Drug Type Small molecule drug |
Synonyms Batefenterol, Batefenterol succinate (USAN), '081 + [4] |
Mechanism mAChRs antagonists(Muscarinic acetylcholine receptor antagonists), β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC44H48ClN5O11 |
InChIKeyBDWHLFQPZLPCIZ-XLQCLRHOSA-N |
CAS Registry945905-37-3 |
Phase 1 | - | 6 | nyhxkiczmg(bqkykmxafn) = affdnlvyql kwyrigbamz (dhpjrxodfv ) View more | - | 01 Nov 2018 | ||
vgicbotdzj(yhilnmhquy) = akyfnuvigw gqoufcwkam (afihmhbcwa ) | |||||||
Phase 2 | 325 | Placebo | rnlihmvbcm(ebuwcjgbzj) = yundsdynnx jscgmfjrdy (koakpiitmq, xlhcxgtrbe - fxitgbmpai) View more | - | 24 Mar 2017 | ||
Phase 2 | 50 | mfvznorwcx(zroopjiote) = n=1, 1200μg dose kyobkmaezx (juzpapaspb ) View more | - | 01 Sep 2011 | |||